These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11481954)

  • 1. [Liver failure with coagulopathy in an infant with tyrosinemia].
    Nussinovitch M; Campino G; Shapira R; Voluvitz B; Amir J
    Harefuah; 2001 Jul; 140(7):578-9, 680. PubMed ID: 11481954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of urinary succinylacetone by capillary electrophoresis for the diagnosis of tyrosinemia type I.
    Cansever MS; Erim FB
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):309-11. PubMed ID: 15734174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutation analysis of FAH gene in patients with tyrosinemia type 1].
    Dou LM; Fang LJ; Wang XH; Lu W; Chen R; Li LT; Zhao J; Wang JS
    Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):302-7. PubMed ID: 23927806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal presentation of a rare metabolic liver disease.
    David JJ; Tullu MS; Rathi P; Sawalakhe N; Ghildiyal RG
    Trop Gastroenterol; 2008; 29(4):229-31. PubMed ID: 19323095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
    Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
    Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosinemia: a report of three cases from India.
    Shah I
    Indian J Gastroenterol; 2013 Mar; 32(2):123-6. PubMed ID: 23408258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong.
    Mak CM; Lam CW; Chim S; Siu TS; Ng KF; Tam S
    Clin Biochem; 2013 Jan; 46(1-2):155-9. PubMed ID: 23000314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
    la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
    Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
    [No Abstract]   [Full Text] [Related]  

  • 9. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
    Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo bleeding time and in vitro thrombelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time.
    Kheirabadi BS; Crissey JM; Deguzman R; Holcomb JB
    J Trauma; 2007 Jun; 62(6):1352-9; discussion 1359-61. PubMed ID: 17563647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of living donor liver transplantation in a Thai boy with hereditary tyrosinemia type I: a case report.
    Jitraruch S; Treepongkaruna S; Teeraratkul S; Wattanasirichaigoon D; Leelaudomlipi S; Sornmayura P; Viengteerawat S; Sriphojanart S
    J Med Assoc Thai; 2011 Oct; 94(10):1276-80. PubMed ID: 22145516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.
    Mohamed S; Kambal MA; Al Jurayyan NA; Al-Nemri A; Babiker A; Hasanato R; Al-Jarallah AS
    BMC Res Notes; 2013 Sep; 6():362. PubMed ID: 24016420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient with urinary succinylacetone-negative hereditary tyrosinemia type 1.
    Mori J; Furukawa T; Kodo K; Nakajima H; Yuasa M; Kubota M; Shigematsu Y
    Pediatr Int; 2023; 65(1):e15644. PubMed ID: 37795850
    [No Abstract]   [Full Text] [Related]  

  • 14. Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure.
    Croffie JM; Gupta SK; Chong SK; Fitzgerald JF
    Pediatrics; 1999 Mar; 103(3):675-8. PubMed ID: 10049978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatorenal Tyrosinemia in Mexico: A Call to Action.
    Ibarra-González I; Ridaura-Sanz C; Fernández-Lainez C; Guillén-López S; Belmont-Martínez L; Vela-Amieva M
    Adv Exp Med Biol; 2017; 959():147-156. PubMed ID: 28755193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.
    Cassiman D; Zeevaert R; Holme E; Kvittingen EA; Jaeken J
    Orphanet J Rare Dis; 2009 Dec; 4():28. PubMed ID: 20003495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit.
    Dempfle CE; Lorenz S; Smolinski M; Wurst M; West S; Houdijk WP; Quintel M; Borggrefe M
    Crit Care Med; 2004 Feb; 32(2):520-4. PubMed ID: 14758173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of early detection and management of disseminated intravascular coagulation among Alexandria University pediatric intensive care patients.
    El-Nawawy A; Abbassy AA; El-Bordiny M; Essawi S
    J Trop Pediatr; 2004 Dec; 50(6):339-47. PubMed ID: 15537719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a neonate with hepatorenal tyrosinemia by combined routine newborn screening for succinylacetone, acylcarnitines and amino acids.
    Al-Dirbashi OY; Fisher L; McRoberts C; Siriwardena K; Geraghty M; Chakraborty P
    Clin Biochem; 2010 May; 43(7-8):691-3. PubMed ID: 19836366
    [No Abstract]   [Full Text] [Related]  

  • 20. Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry.
    Al-Dirbashi OY; Rashed MS; Brink HJ; Jakobs C; Filimban N; Al-Ahaidib LY; Jacob M; Al-Sayed MM; Al-Hassnan Z; Faqeih E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):274-80. PubMed ID: 16384749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.